▶주메뉴 바로가기
▶본문 바로가기
Koreas intravenous solution maker JW Life Science announced on Feb. 18 that it has decided to give 500 won (US$0.44) dividend per share, which amounts to around 7.91 billion won in total. Establishe...
Korean drug maker Kwangdong Pharmaceutical, which has been focusing on diversifying its business portfolio, appears to be making attempts at a turnaround amid its slumping global business. The Korea...
SK Biopharmaceuticals, the new drug development subsidiary of South Korean conglomerate SK Group, announced on Feb. 14 that it had signed a deal worth US$530 million with Swiss drug company Arvelle T...
CJ Healthcare announced on Feb. 13 that it has signed a deal worth US$84 million with Mexico-based Laboratorios Carnot to exclusively supply its drug Tegoprazan for the next 10 years. Tegoprazan, wh...
Korean firms Genexine and SCM Life science announced on Feb. 13 that they have jointly acquired US biotech firm Argos Therapeutics for around 12.5 billion won (US$ 11.14 million) through an auction...
Korean biotech firm Bridge Biotherapeutics is aiming to get listed on the second-tier KOSDAQ market this year, having picked KB Securities and Daishin Securities as its IPO manager, according to comp...
Korean drug developer Samsung Bioepis announced Feb. 11 that it has inked a partnership with Chinese private equity firm C-Bridge Capital. “We expect C-Bridge to be a great partner for our business ...
Shares of Daewoong Pharmaceutical have been rallying since the company announced on Jan. 1 that its botulinum toxin Nabota received marketing authorization from the US Food and Drug Administration. ...
New drug developer Voronoi is seeking to raise fresh funds worth 100 billion won (US$89 million) ahead of a potential initial public offering, according to news reports on Feb. 8. Established in 201...
Daewoong Pharmaceutical Chairman Jeon Seung-ho on Feb. 1 strongly refuted allegations by its rivals that it stole manufacturing secrets to develop botulinum toxin Nabota. The announcement came after...
[THE INVESTOR] Korean drug maker KyungDong Pharmaceutical said on Feb. 1 that it has invested 1 billion won (US$894,694) in a biotech and health care related startup focused fund led by venture capi...
[THE INVESTOR] Korean 3D bio-printer maker Rokit has secured 11 billion won (US$9.89 million) in funding from KB Investment, Korea Development Bank and DAYLI Partners, according to sources on Jan.31...
[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis saw its accumulated sales in the European market hit US$545.2 million last year, data showed on Jan. 30. Sales of three biosimilar produ...
[THE INVESTOR] Genosco, a US-based subsidiary of Korean bio company Oscotec, is gearing up to go public, according to industry sources on Jan. 28. The company recently sent out a request for propos...
[THE INVESTOR] LG Household & Health Care said on Jan. 24 its net profit jumped 12 percent on-year fueled by the popularity of its luxury cosmetics brands. Its net profit came to 692 billion won...
NH NongHyup launches biometric boarding service
Ex-presidential adviser named head of Korea’s sovereign wealth fund
KakaoBank’s Q1 net profit jumps 150%
KB Asset raises W1tr for AMP Capital’s infra debt funds
Climate response fund to be set up in 2022 to bolster renewable energy transition
Middle-income households see sharpest drop in spending
MMAA hires ex-Lotte insurance CIO
Real estate fiasco sidelines Moon’s income-led growth drive
May 19, 2021
